PT - JOURNAL ARTICLE AU - Narkwichean, Amarin AU - Jomoui, Wittaya AU - Boonpradit, Rarinthip AU - Laosooksathit, Wipada AU - Nopsopon, Tanawin AU - Pongpirul, Krit TI - Potential applications of the rapid COVID-19 antibody test kit screening in comparison to the RT-PCR in patients and personnel at the Department of Obstetrics and Gynecology AID - 10.1101/2021.07.16.21259725 DP - 2021 Jan 01 TA - medRxiv PG - 2021.07.16.21259725 4099 - http://medrxiv.org/content/early/2021/07/20/2021.07.16.21259725.short 4100 - http://medrxiv.org/content/early/2021/07/20/2021.07.16.21259725.full AB - Objective To explore potential applications of the rapid antibody test for COVID-19 screening, in comparison to RT-PCR, for emergency obstetric and gynecological procedures, and medical personnel in the Department of Obstetrics and Gynecology.Methods A cross-sectional study was conducted in expected 290 participants: 230 patients and 60 medical staff, during the four-month national COVID-19 outbreak period (Aug – Sep 2020, and Dec 2020 - Jan 2021). All participants underwent both rapid antibody tests and RT-PCR (at admission for patients).Results A total of 270 participants completed the study. Fever and URI symptoms were present in 6/210 patients (2.8%) while one patient (0.5%) had a history of traveling to a high-risk area. However, only two (1%) asymptomatic patients had positive IgM results. Concerning the medical personnel, 10% fell into the ‘patient under investigation (PUI)’ category. 4/60 (6.7%) IgM positive was observed in the staff cohort in which 3/4 came from non-PUI participants. Neither participant had RT-PCR positive demonstrating a 1.9% total false positive rate.Conclusion Rapid point-of-care antibody test can be used to screen either a pregnant coming for delivery, a patient who requires urgent/emergency operative procedures, or medical personnel, at least in the defined lower-prevalence COVID-19 situation.Trial registration This study was approved by the Institutional Review Board of Srinakharinwirot University (IRB SWUEC119/2563F) and was registered at the Thai Clinical Trials Registry (TCTR20210613001).Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThai Clinical Trials Registry: TCTR20210613001Clinical Protocols https://www.thaiclinicaltrials.org/ Funding StatementThe study received full financial support from the Health System Research Institute (Thai government agencies), Thailand.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Institutional Review Board of Srinakharinwirot University (IRB SWUEC119/2563F).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data relevant to the study are included in the article. De-identified data of this study could be shared upon request.